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Abstract 
Background: Depression is associated with increased mortality among patients with chronic 
heart failure (HF). Whether depression is an independent predictor of outcome in patients 
admitted for worsening of HF is unclear.  
Methods: OPERA-HF is an observational study enrolling patients hospitalized with worsening 
HF. Depression was assessed by the Hospital Anxiety and Depression Scale (HADS-D) 
questionnaire. Comorbidity was assessed by the Charlson Comorbidity Index (CCI). Kaplan-
Meier and Cox regression analyses were used to estimate the association between depression and 
all-cause mortality.  
Results: Of 242 patients who completed the HADS-D questionnaire, 153, 54 and 35 patients had 
no (score 0-7), mild (score 8-10) or moderate-to-severe (score 11-21) depression, respectively. 
During follow-up, 35 patients died, with a median time follow-up of 360 days amongst survivors 
(interquartile range, IQR 217 - 574 days). In univariable analysis, moderate-to-severe depression 
was associated with an increased risk of death (HR: 4.9; 95% CI: 2.3 to 10.2; P < 0.001) 
compared to no depression. Moderate-to-severe depression also predicted all-cause mortality 
after controlling for age, CCI score, NYHA class IV, NT-proBNP and treatment with 
mineralocorticoid receptor antagonist, beta-blocker and diuretics (HR: 3.0; 95% CI: 1.3 to 7.0; P 
< 0.05).  
Conclusions: Depression is strongly associated with an adverse outcome in the year following 
discharge after an admission to hospital for worsening HF. The association is only partly 
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explained by the severity of HF or comorbidity. Further research is required to demonstrate 
whether recognition and treatment of depression improves patient outcomes. 
Keywords: Heart failure; mortality; depression; risk factor.
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1. Introduction 
Psychosocial illness, including depression, is common in people with cardiovascular 
disease. Depression is particularly common in patients with heart failure (HF) 
1
. Probably most 
patients with HF are depressed by their illness at some time but a meta-analysis suggests that 
depression affects about a 20% of patients at any time 
2
.  
For patients with HF, depression is associated with an increased rate of adverse outcomes 
2,3
, such as hospitalization and death. The aggregated risk-estimate derived from 26 studies was 
an approximately 1.5-fold risk of death in patients with HF if they had depression (3). However, 
it can be difficult to disentangle whether depression causes a worse outcome, or merely reflects 
worse HF or more severe co-morbidity. We aimed to assess the prevalence and consequences of 
depression in patients admitted to hospital for worsening HF. We analyzed a prospective patient 
cohort and controlled for common covariates reflecting the severity of both the HF and any 
comorbidities.  
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2. Methods 
2.1. Study design 
OPERA-HF is an ongoing prospective observational study, enrolling patients hospitalized 
with worsening heart failure (WHF) to the Hull & East Yorkshire Hospitals NHS Trust, UK. The 
aim of the study is to gather a holistic view of the patients, their general condition and co-
morbidities, and to identify predictors of mortality and re-admission to hospital. Clinical and 
psycho-social data were collected during hospital admission and just prior to discharge. The 
Charlson comorbidity index (CCI) was used to assess comorbidity (Appendix A). 
Patients had to fulfill all of the following criteria to be included in the study: age >18 
years; hospitalization for WHF; treatment with loop diuretics; and at least one of the following: 
left ventricular ejection fraction ≤ 40%, left atrial dimension >4.0 cm or NT-ProBNP >400 pg/ml 
(if in sinus rhythm) or >1200 pg/ml (if in atrial fibrillation). Patients unable to understand and 
comply with the protocol or unable or unwilling to give informed consent were excluded from 
the study. The study has full ethical approval from the South Yorkshire Research Ethics 
Committee (REC ref: 12/YH/0344) and is conducted in accordance with ICH-GCP, Declaration 
of Helsinki, the Data Protection Act 1998 and the NHS Act 2006.  
2.2. Depression assessment 
Depression was assessed by the Hospital Anxiety and Depression Scale (HADS-D) 
questionnaire 
4
 (Appendix B). The HADS-D focuses on questions about depression. The 
response to each of the 7 questions is graded from 0 to 3, giving a total score that ranges between 
0 and 21. A score of 7 or less implies that there is no depression; a score of 8-10 suggests mild 
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depression; and a score of 11 reflects moderate-to-severe depression 
4
. Among 12 studies 
assessing the HADS-D questionnaire (total N = 2109 patients), a cut point of 8 for the diagnosis 
of depression had a mean specificity of 0.79 and a mean sensitivity of 0.83 when compared with 
a ‘gold standard’ diagnosis using DSM-III/IV or similar codes 5. 
2.3. Mortality 
All patients enrolled in the study are followed subsequent to discharge. Readmissions and 
all-cause mortality are automatically recorded in the hospital’s IT system. For the present report, 
the primary outcome of interest was all-cause mortality.  
2.4. Statistical analysis 
We report the baseline characteristics of the patients who participated in the study 
between 14/10/2012 and 16/06/2015 and who completed the HADS-D questionnaire. Follow up 
was censored at 13/07/2015. The consort diagram is given in Appendix C.  
Univariable and multivariable Cox proportional hazard regression models were used to 
estimate the association between depression and all-cause mortality. Univariable analysis was 
performed to assess the relation between variables and outcome, including demographics, 
clinical assessment, echocardiography and medication. In the multivariable model, we adjusted 
for all the variables found to predict outcome (P ≤ 0.1) in the univariable analysis. Multiple 
imputation 
6
 was used to impute missing data when need. The Kaplan-Meier method was used to 
estimate survival time and produce a survival curve 
7
. All analyses were conducted using R 3.1.3 
statistical software (The R Foundation for Statistical Computing, Vienna, Austria). In particular, 
the R package mice 
8
 was used for the multiple imputation and the R package survival 
9
 for the 
Kaplan-Meier method and the survival analysis.
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3. Results 
3.1. Baseline characteristics of the study population 
 The baseline characteristics of the 242 participants who completed the HADS-D 
questionnaire are reported in Table 1. The median follow-up was 315 days (interquartile range, 
IQR 167 - 519) for all patients and 360 days (IQR = 217 - 574) amongst survivors. The mortality 
rate estimated from the Kaplan Meier curve was 15% [95% CI 10% - 20%] at one year.  
 Table 1 
3.2. Depression assessment 
 The median HADS-D score amongst the 242 HF patients was 6 (IQR = 3 - 9); 153 
patients had no (score 0-7), 54 had mild (score 8-10) and 35 had moderate-to-severe (score 11-
21) depression, respectively. Patients with moderate-to-severe depression were, on average, in a 
worse NYHA class, had more likely sinus heart rhythm and were taking more HF medications 
than those with no depression Table 1.  
 Patients were more likely to give high (i.e. worse) scores to the questions “I can laugh 
and see the funny side of things” and “I feel as if I am slowed down” Table 2. 
 Table 2 
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3.3. Effect of depression on mortality 
 The unadjusted rate for all-cause mortality was almost five times higher amongst patients 
with moderate-to-severe depression compared to patients without depression (HR: 4.9; 95% CI: 
2.3 to 10.2; P < 0.001, Table 3a and Figure 1). Increasing age (as a continuous variable), 
increasing NT-proBNP (continuous), NYHA class IV within 7 days before admission  
(compared with patients with Class I/II), increasing CCI score, and use of a mineralocorticoid 
receptor antagonist, beta-blocker and diuretic were all associated with increasing mortality. We 
therefore corrected for these characteristics in the multivariable analysis Table 3b). Moderate-to-
severe depression remained a significant predictor of all-cause mortality (HR: 3.0; 95% CI: 1.3 
to 7.0; P < 0.05) along with NT-proBNP (HR: 1.7; 95% CI: 1.1 to 2.8; P < 0.05) and NYHA 
class IV (HR: 1.2; 95% CI: 1.0 to 4.6; P < 0.1). Further details on the association between the 
covariates and the outcome are provided in Table 4 (Appendix D).  
Table 3 
Figure 1 
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4. Discussion 
Amongst patients admitted to hospital with worsening heart failure, the presence of 
moderate to severe depression is a strong predictor of mortality subsequent to discharge, even 
after correcting for potential confounders. This is consistent with evidence suggesting that 
depression predicts mortality amongst patients with chronic HF 
2,3
 but the relationship may be 
even stronger for those admitted to hospital with worsening heart failure.  
Whether the association between depression and mortality is causal and, if so, whether 
targeting this link could improve prognosis remains uncertain. Pessimism and depression may 
have biological effects that adversely affect prognosis 
10
. Alternatively, depression may reduce 
adherence to life-style advice and heart failure medications leading to a worse prognosis 
11,12
 . 
Health care professionals might be unconsciously less attentive to depressed patients. Finally, it 
is possible that we did not identify and measure some key prognostic variables; some patients 
may be depressed because they not only feel sicker but are indeed sicker. The clinical reality is 
that all of the above are probably relevant to different patients at different times. Teasing out 
which is the most important for an individual patient may be difficult.    
It is unclear whether the recognition and management of depression might improve 
patient outcomes. Randomized trials of drug intervention with selective serotonin re-uptake 
inhibitors have been disappointing  
13,14
. Interestingly, many patients admitted to hospital with 
worsening heart failure report good quality of life after discharge 
15
. Maybe improving the 
patients’ perception of their future and their enjoyment of their lives would have a positive 
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feedback that improves outcome. Perhaps the focus should also be on serial assessment with 
intervention only when depression persists despite simple measures such as good treatment of 
the medical condition, social support and attention to health fears and loneliness. Trials of new 
interventions, such as cognitive behavioral therapy, use of self-management plans delivered by 
community health care teams or by tele-monitoring might be effective alternatives to drug 
therapy 
16
. Tackling the problems that depression causes rather than depression itself could also 
be important; a diagnosis of depression should heighten awareness of the need for support, 
advice and encouragement of adherence. 
Mild depression was not strongly associated with mortality in either the univariable or 
multivariable models. This may reflect the attributes of the HADS score; several questions could 
reflect the severity of functional impairment due to HF itself rather than depression. For instance, 
one question asks the patient to rate this statement “I feel as if I am slowed down”; most patients 
gave themselves poor scores on this question, which could be interpreted as the inability to 
exercise due to heart failure: however, it leads to patients being given a HADS score suggesting 
mild depression.  
Most patients gave themselves a worst-rank score for the statement “I can laugh and see 
the funny side of things”. For other questions, there was a wider distribution of scores. It is not 
clear that the relatively complex questionnaires currently used to assess mood and quality of life 
are superior to single, simple, direct, intuitive questions in detecting important depression (“Are 
you depressed? If so, how badly does this affect you?”) or assessing well-being (“On a scale of 
1-10 how well are you today?”); single questions are easy to administer and may be more 
efficient, although they may need to be interpreted in the context of the patients situation (for 
example, recent near-death experience, worsening heart failure or stable CHF) 
17
. Indeed, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
responses to just two-questions (PHQ-2) appears to identify patients with depression fairly 
accurately compared to more complex instruments 
18
.  
Other Limitations. The study is relatively small, with a modest number of events, but it is 
one of the first in patients hospitalized with WHF. The diagnosis of depression was made with a 
tool that does not give the same diagnostic certainty as DSM-III/IV or similar codes. The tool 
was only administered once, and we may have missed changes in mood during or after 
hospitalization. The HADS uses some colloquial language which may not be understood by 
patients from different backgrounds.  
Conclusion. Moderate to severe depression is strongly associated with mortality in the 
year following discharge after a HF admission to hospital. The association is independent of HF 
severity and other comorbidity. New strategies are required to improve the recognition of 
depression and to target those with persistent problems who might benefit from intervention.  
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Figure legends 
Figure 1 Cumulative incidence plot – (a) unadjusted and (b) adjusted for age (continuous), CCI score 
(continuous), NYHA class IV (worst NYHA class during 7 days before admission - binary), log(NT-
proBNP) (continuous), Aldosterone Antagonist (binary), Beta-blocker (binary) and diuretics (binary) 
[applied on the imputed dataset] ................................................................................................................. 28 
Figure 2 Consort diagram ........................................................................................................................... 29 
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Appendices 
A. Charlson Comorbidity Index (CCI)  
Comorbidity is assessed by Charlson Comorbidity Index (CCI) 
19
. CCI is calculated during 
hospitalization by assigning to certain comorbidities a weighted value. 
– 1 point 
Myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, 
cerebrovascular disease, chronic pulmonary disease, connective tissue disease, ulcer disease, 
mild liver disease, diabetes. 
– 2 points:  
Hemiplegia, moderate or severe renal disease, diabetes with end organ damage, any tumor, 
leukemia, lymphoma. 
– 3 points:  
Moderate or severe liver disease. 
– 6 points:  
Metastatic solid tumor, AIDS. 
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B. HADS-D questionnaire items 4 
In this analysis the depression related part of the HADS questionnaire is used. This part consists 
of the following seven questions and four possible answers per question. 
1. I still enjoy the things I used to enjoy 
a. Definitely as much 
b. Not quite so much 
c. Only a little 
d. Hardly at all 
2. I can laugh and see the funny side of things 
a. As much as I always could 
b. Not quite so much now 
c. Definitely not so much now 
d. Not at all 
3. I feel cheerful 
a. Not at all 
b. Not often 
c. Sometimes 
d. Most of the time 
4. I feel as if I am slowed down 
a. Nearly all the time 
b. Very often 
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c. Sometimes 
d. Not at all 
5. I have lost interest in my appearance 
a. Definitely 
b. I don't take so much care as I should 
c. I may not take quite as much care 
d. I take just as much care as ever 
6. I look forward with enjoyment to things 
a. As much as ever I did 
b. Rather less than I used to 
c. Definitely less than I used t o 
d. Hardly at all 
7. I can enjoy a good book or radio or TV program 
a. Often 
b. Sometimes 
c. Not often 
d. Very seldom 
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C. Consort diagram 
The consort diagram of the study is shown in Figure 2. 
 Figure 2 
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D. Univariable/Multivariable analysis. 
In Table 4 the results of the univariable and multivariable Cox regression analysis are provided.  
 Table 4
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
 
Tables 
Table 1 Baseline characteristics stratified by HADS-D group and total population. Characteristics are 
summarized by their count and fraction (N (%)) for categorical or their median and interquartile range 
(Median [25th – 75th]) for continuous variables, respectively; (*) all variables are evaluated at admission 
apart from NT-proBNP and LVEF which are evaluated at discharge and (**) NYHA class which was 
evaluated as the worst class during the last 7-days before admission (***) Diuretics: loop diuretics or 
thiazide 
Depression Score All (N=242) 0 – 7 (N=153) 8-10 (N=54) 11-21 (N=35) 
Characteristics (*) 
Valid 
N 
Summary 
Valid 
N 
Summary 
Valid 
N 
Summary 
Valid 
N 
Summary 
Women, % 242 76 (31%) 153 48 (31%) 54 18 (33%) 35 10 (29%) 
Age, years 242 
74 [ 64 – 
80] 
153 
73 [64 – 
81] 
54 
74 [67 – 
78] 
35 
73 [63 – 
80] 
CCI, score 221 3 [2 – 5] 143 3 [2 – 4] 46 3 [2 – 6] 32 3 [2 – 5] 
NYHA**: Class I/II, % 
NYHA: Class III, % 
NYHA: Class IV, % 
209 
209 
209 
32 (15%) 
135(65%) 
42 (20%) 
132 
132 
132 
23 (18%) 
87 (66%) 
22 (17%) 
48 
48 
48 
7 (15%) 
32 (67%) 
9 (19%) 
29 
29 
29 
2 (6%) 
16 (55%) 
11 (38%) 
Hypertension, % 235 
130 
(55%) 
150 82 (55%) 53 27 (51%) 32 21 (66%) 
NT-proBNP, pg/mL 204 
4792 
[1694 – 
9784] 
130 
5022 
[1782– 
9668] 
45 
3188 
[1323 – 
9445] 
29 
5368 
[2830 – 
12290] 
Heart Rhythm: Sinus, % 242 92 (38%) 153 50 (33%) 54 25 (46%) 35 17 (49%) 
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LVEF at discharge: 
≤40% 
216 128(59%) 142 89 (63%) 48 23 (48%) 26 16 (62%) 
Main presentation: 
- Severe peripheral 
oedema, % 
- Severe breathlessness at 
rest, % 
- Increasing exertional 
breathlessness, % 
- Chest pain - cardiac, % 
- Other symptom, % 
 
236 
 
236 
 
236 
 
236 
236 
 
24 (10%) 
 
76 (32%) 
 
106(45%) 
 
21 (9%) 
9 (4%) 
 
149 
 
149 
 
149 
 
149 
149 
 
19 (13%) 
 
56 (38%) 
 
53 (36%) 
 
14 (9%) 
7 (5%) 
 
52 
 
52 
 
52 
 
52 
52 
 
3 (6%) 
 
12 (23%) 
 
31 (60%) 
 
6 (11%) 
0 (0%) 
 
35 
 
35 
 
35 
 
35 
35 
 
2 (6%) 
 
8 (23%) 
 
22 (63%) 
 
1 (3%) 
2 (6%) 
HF Medication (on 
admission) 
ACE inhibitor, % 
ARB , %  
Beta-blocker, % 
Aldosterone 
Antagonist,% 
Digitalis, % 
Diuretics ***, % 
 
 
242 
242 
242 
242 
 
242 
242 
 
 
98 (40%) 
48 (20%) 
126(52%) 
51 (21%) 
 
35 (14%) 
128(53%) 
 
 
153 
153 
153 
153 
 
153 
153 
 
 
54 (35%) 
30 (20%) 
70 (46%) 
29 (19%) 
 
19 (12%) 
71 (46%) 
 
 
54 
54 
54 
54 
 
54 
54 
 
 
24 (44%) 
12 (22%) 
32 (59%) 
11 (20%) 
 
9 (17%) 
30 (56%) 
 
 
35 
35 
35 
35 
 
35 
35 
 
 
20 (57%) 
6 (17%) 
24 (69%) 
11 (31%) 
 
7 (20%) 
27 (77%) 
NYHA, New York Heart Association; CCI, Charlson comorbidity index; LVEF, Left ventricular ejection fraction; SOB, Acute 
shortness of breath; ACE, Angiotensin-converting enzyme; ARB: Angiotensin Receptor Blockers. 
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Table 2 Patients scoring of HADS-D questions; the score for each question ranges from 0 (as the most positive response) 
to 3 (most negative response). The aggregated scores are calculated based on the 242 HF patients answering the HADS-D 
questionnaire. 
Question Score per answer Number of 
patients 
Aggregated 
score for 242 
patients 
I still enjoy the things I used to enjoy Definitely as much - 0 
Not quite so much - 1 
Only a little - 2 
Hardly at all - 3 
58 
109 
40 
35 
294 
I can laugh and see the funny side of 
things 
As much as I always could - 0 
Not quite so much now -  1 
Definitely not so much now - 2 
Not at all - 3 
1 
18 
64 
159 
623 
I feel cheerful Most of the time – 0 
Sometimes - 1  
Not often - 2 
Not at all - 3 
145 
79 
14 
4 
119 
I feel as if I am slowed down Not at all – 0 
Sometimes - 1 
Very often - 2 
Nearly all the time - 3 
12 
78 
62 
90 
472 
I have lost interest in my appearance I take just as much care as ever – 0 
I may not take quite as much care - 1 
I don't take so much care as I should - 2 
Definitely - 3 
117 
65 
51 
9 
194 
I look forward with enjoyment to things As much as ever I did - 0 
Rather less than I used to - 1 
Definitely less than I used to - 2 
Hardly at all - 3 
94 
85 
50 
13 
224 
I can enjoy a good book or radio or TV 
program 
Often – 0 
Sometimes - 1 
Not often - 2 
Very seldom - 3 
155 
59 
17 
11 
126 
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Table 3 (a) Univariable analysis, (b) Multivariable analysis; (*) HR based on Cox proportional hazard models;  (**) 
adjusted for age (continuous), CCI score (continuous), NYHA class IV (worst NYHA class during 7 days before admission 
- binary), log(NT-proBNP) (continuous), Aldosterone Antagonist (binary), Beta-blocker (binary) and diuretics (binary) 
(a) Univariable analysis (N = 242 / events = 35) - Likelihood ratio test = 15.25 for 2df, p<0.001 
Depression status at admission 
HR for All-Cause 
Mortality* 
95% CI P-value 
None (reference) 
Mild 
Moderate-to-severe 
1.00 
1.54 
4.86 
– 
0.63 – 3.80 
2.30 – 10.25  
– 
 0.34 
<0.001 
    (b) Multivariable analysis** (N = 242 / events = 35) - Likelihood ratio test = 41.5 for 9df, p<0.001 
Depression status at admission 
HR for All-Cause 
Mortality 
95% CI P-value 
None (reference)  
Mild 
Moderate-to-severe 
1.00 
1.44 
2.97 
– 
0.58 – 3.63 
1.26 – 6.99 
– 
 0.44 
<0.05 
HR, Hazard Ratio; CI, Confidence Interval. 
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Table 4 Univariable/Multivariable analysis 
 
Univariable analysis 
(N = 242 / events = 35) 
Multivariable analysis 
(N = 242 / events = 35) 
 HR 95% CI P-value HR 95% CI P-value 
Women, yes 0.78 0.37 – 1.67 0.52 - - - 
Age at admission (HR for 10 year increase) 1.68 1.17 – 2.30 <0.01* 1.62 0.84 – 3.21 0.16 
CCI at admission, score (HR for 1 unit 
increase in the score) 
1.13 1.00  – 1.29 <0.1* 1.08 0.93 – 1.26 0.39 
NYHA**: Class I or II (reference) 
NYHA: Class III 
NYHA: Class IV 
1 
0.72 
2.62 
– 
0.26 – 2.02 
0.95 – 7.27 
– 
0.52 
<0.1* 
 
- 
2.15 
 
- 
1.00 - 4.59 
 
- 
<0.1* 
Hypertension at admission, yes 0.85 0.43 – 1.65 0.63 - - - 
Log10(NT-proBNP) at discharge, pg/mL 
(HR for 1 unit increase in the logarithmic 
scale) 
2.75 1.32  – 5.75 <0.05* 1.69 1.07 – 2.76 <0.05* 
Heart Rhythm at admission: Sinus 1.17 0.60 – 2.28 0.65 - - - 
LVEF at discharge: ≤40% 1.48 0.72 – 3.04 0.30 - - - 
Main presentation: 
- Severe peripheral oedema, yes 
- Severe breathlessness at rest, yes 
- Increasing exertional breathlessness, yes 
- Chest pain - cardiac, yes 
- Other symptom, yes 
 
1 
0.42 
0.48 
0.26 
0.35 
 
– 
0.15 – 1.14 
0.18 – 1.25 
0.05 – 1.31 
0.04 – 2.93 
 
– 
0.11 
0.13 
0.11 
0.33 
- - - 
HF Medication at admission 
- ACE inhibitor, yes 
-ARB, yes 
-Beta-blocker, yes 
-Aldosterone Antagonist, yes 
-Digitalis, yes 
-Diuretics, yes 
 
1.67 
1.27 
2.54 
2.27 
1.36 
2.44 
 
0.86 – 3.25 
0.58 – 2.79 
1.22  – 5.29 
1.13 – 4.58 
0.56 – 3.27 
1.17 – 5.09 
 
0.13 
0.56 
<0.1* 
<0.1* 
0.50 
<0.05* 
 
- 
- 
1.86 
1.69 
- 
1.10 
 
- 
- 
0.87 –3.99 
0.79 – 3.62 
- 
0.48 – 2.53 
 
- 
- 
0.15 
0.18 
- 
0. 82 
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HR, Hazard Ratio; CI, Confidence Interval; NYHA, New York Heart Association; CCI, Charlson comorbidity index; LVEF, Left ventricular 
ejection fraction; ACE, Angiotensin-converting enzyme; ARB: Angiotensin Receptor Blockers. 
*significance level of 0.1  
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Figures 
 
Figure 1 Cumulative incidence plot – (a) unadjusted and (b) adjusted for age (continuous), CCI score (continuous), 
NYHA class IV (worst NYHA class during 7 days before admission - binary), log(NT-proBNP) (continuous), Aldosterone 
Antagonist (binary), Beta-blocker (binary) and diuretics (binary) [analysis based on the imputed dataset] 
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Figure 2 Consort diagram 
